BACKGROUND: Low vitamin D intake and levels have been associated with increased joint symptoms in some observational studies but the findings are mixed and evidence from randomized trials sparse. OBJECTIVE: To evaluate the influence of supplemental calcium and vitamin D on joint symptoms in the Women's Health Initiative randomized, placebo-controlled, clinical trial. DESIGN: In post hoc analyses, the results of the Women's Health Initiative randomized clinical trial in which 36,282 postmenopausal women were randomized to receive calcium carbonate (1,000 mg as elemental calcium) with vitamin D-3 (400 IU) daily or placebo were examined in the 6% subgroup of 1,911 participants, oversampled for minorities, who had serial joint symptom assessment. Qualitative information on joint pain and joint swelling was collected by questionnaire before entry and 2 years after randomization. Logistic regression models were used to compare the occurrence and severity of joint symptoms across randomization groups. RESULTS: At baseline, total calcium and vitamin D intakes from diet and supplements were similar in the two randomization groups. In addition, both joint pain (reported by 73%) and joint swelling (reported by 34%) were commonly reported and comparable in the supplement and placebo groups. Two years after randomization, no statistically significant differences between supplement and placebo groups were seen for joint pain frequency (74.6% compared with 75.1% [P=0.79] for supplement and placebo groups, respectively) or joint swelling frequency (34.6% compared with 32.4% [P=0.29], respectively) or in severity scores for either outcome. Subgroup analyses suggested study participants also using nonprotocol calcium supplements at study entry may have less joint pain with supplement group randomization (interaction P=0.02). CONCLUSIONS:Joint symptoms are relatively common in postmenopausal women. However, daily supplementation with 1,000 mg calcium carbonate and 400 IU vitamin D-3 in a randomized, placebo-controlled clinical trial setting did not reduce the self-reported frequency or severity of joint symptoms.
RCT Entities:
BACKGROUND: Low vitamin D intake and levels have been associated with increased joint symptoms in some observational studies but the findings are mixed and evidence from randomized trials sparse. OBJECTIVE: To evaluate the influence of supplemental calcium and vitamin D on joint symptoms in the Women's Health Initiative randomized, placebo-controlled, clinical trial. DESIGN: In post hoc analyses, the results of the Women's Health Initiative randomized clinical trial in which 36,282 postmenopausal women were randomized to receive calcium carbonate (1,000 mg as elemental calcium) with vitamin D-3 (400 IU) daily or placebo were examined in the 6% subgroup of 1,911 participants, oversampled for minorities, who had serial joint symptom assessment. Qualitative information on joint pain and joint swelling was collected by questionnaire before entry and 2 years after randomization. Logistic regression models were used to compare the occurrence and severity of joint symptoms across randomization groups. RESULTS: At baseline, total calcium and vitamin D intakes from diet and supplements were similar in the two randomization groups. In addition, both joint pain (reported by 73%) and joint swelling (reported by 34%) were commonly reported and comparable in the supplement and placebo groups. Two years after randomization, no statistically significant differences between supplement and placebo groups were seen for joint pain frequency (74.6% compared with 75.1% [P=0.79] for supplement and placebo groups, respectively) or joint swelling frequency (34.6% compared with 32.4% [P=0.29], respectively) or in severity scores for either outcome. Subgroup analyses suggested study participants also using nonprotocol calcium supplements at study entry may have less joint pain with supplement group randomization (interaction P=0.02). CONCLUSIONS: Joint symptoms are relatively common in postmenopausal women. However, daily supplementation with 1,000 mg calcium carbonate and 400 IU vitamin D-3 in a randomized, placebo-controlled clinical trial setting did not reduce the self-reported frequency or severity of joint symptoms.
Authors: Antonella L Rastelli; Marie E Taylor; Feng Gao; Reina Armamento-Villareal; Shohreh Jamalabadi-Majidi; Nicola Napoli; Matthew J Ellis Journal: Breast Cancer Res Treat Date: 2011-06-21 Impact factor: 4.872
Authors: Anne McTiernan; Charles Kooperberg; Emily White; Sara Wilcox; Ralph Coates; Lucile L Adams-Campbell; Nancy Woods; Judith Ockene Journal: JAMA Date: 2003-09-10 Impact factor: 56.272
Authors: Arjan P Bergink; André G Uitterlinden; Johannes P T M Van Leeuwen; Cok J Buurman; Albert Hofman; Jan A N Verhaar; Huibert A P Pols Journal: J Clin Rheumatol Date: 2009-08 Impact factor: 3.517
Authors: Rowan T Chlebowski; Karen C Johnson; Charles Kooperberg; Mary Pettinger; Jean Wactawski-Wende; Tom Rohan; Jacques Rossouw; Dorothy Lane; Mary Jo O'Sullivan; Shagufta Yasmeen; Robert A Hiatt; James M Shikany; Mara Vitolins; Janu Khandekar; F Allan Hubbell Journal: J Natl Cancer Inst Date: 2008-11-11 Impact factor: 13.506
Authors: S Muraki; E Dennison; K Jameson; B J Boucher; T Akune; N Yoshimura; A Judge; N K Arden; K Javaid; C Cooper Journal: Osteoarthritis Cartilage Date: 2011-08-16 Impact factor: 6.576
Authors: Piotr Bełdowski; Maciej Przybyłek; Przemysław Raczyński; Andra Dedinaite; Krzysztof Górny; Florian Wieland; Zbigniew Dendzik; Alina Sionkowska; Per M Claesson Journal: Int J Mol Sci Date: 2021-11-16 Impact factor: 5.923
Authors: N K Arden; S Cro; S Sheard; C J Doré; A Bara; S A Tebbs; D J Hunter; S James; C Cooper; T W O'Neill; A Macgregor; F Birrell; R Keen Journal: Osteoarthritis Cartilage Date: 2016-06-02 Impact factor: 6.576